Chimeric Therapeutics Limited (ASX:CHM)

Market Cap	9.76M
Revenue (ttm)	2.04M
Net Income (ttm)	-17.83M
Shares Out	3.25B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,323
Average Volume	8,552,630
Open	0.0030
Previous Close	0.0030
Day's Range	0.0030 - 0.0030
52-Week Range	0.0030 - 0.0200
Beta	1.54
RSI	44.99
Earnings Date	Aug 29, 2025

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17 CAR T cell therapy that is in Phase I/II multi-centre clinical trials for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a Chlorotoxin CAR T cell therapy, which is in phase Ia/IIb clinical trials for patients with recurrent or progressive Glioblastoma, as well as in preclinical trials for MMP2 express...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

In 2024, Chimeric Therapeutics's revenue was 7.46 million, an increase of 65.52% compared to the previous year's 4.51 million. Losses were -12.53 million, -51.65% less than in 2023.